News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How Bristol-Myers Squibb (BMY) And Pfizer (PFE) Are Stomping On Their Blood Thinner Rivals



2/17/2017 6:45:25 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Warfarin may have dominanted the $10 billion market for anticoagulants for the past 50 or so years, but a new class of drugs that works in an entirely new way is quickly relegating warfarin's use to the dustbin. Factor Xa inhibitors that keep blood clots from forming without targeting vitamin K like warfarin are generating billions of dollars per year in sales.

Currently, Bristol-Myers Squibb and Pfizer Inc.'s Eliquis is the top-selling factor Xa, but other companies are also fighting for share, including Johnson & Johnson, which markets the blockbuster Xarelto. Can Eliquis keep Bristol-Myers Squibb and Pfizer on top in this indication?

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES